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Abstract
Introduction: PIK3CA is the oncogene showing the highest frequency of gain-of-function mutations in breast
cancer, but the prognostic value of PIK3CA mutation status is controversial.
Methods: We investigated the prognostic significance of PIK3CA mutation status in a series of 452 patients with
unilateral invasive primary breast cancer and known long-term outcome (median follow-up 10 years).
Results: PIK3CA mutations were identified in 151 tumors (33.4%). The frequency of PIK3CA mutations differed
markedly according to hormone receptor (estrogen receptor alpha [ERa] and progesterone receptor [PR]) and
ERBB2 status, ranging from 12.5% in the triple-negative subgroup (ER-/PR-/ERBB2-) to 41.1% in the HR+/ERBB2-
subgroup. PIK3CA mutation was associated with significantly longer metastasis-free survival in the overall
population (P = 0.0056), and especially in the PR-positive and ERBB2-positive subgroups. In Cox multivariate
regression analysis, the prognostic significance of PIK3CA mutation status persisted only in the ERBB2-positive
subgroup.
Conclusions: This study confirms the high prevalence of PIK3CA mutations in breast cancer. PIK3CA mutation is an
emerging tumor marker which might become used in treatment-choosing process. The independent prognostic
value of PIK3CA mutation status in ERBB2-positive breast cancer patients should be now confirmed in larger series
of patients included in randomized prospective ERBB2-based clinical trials.
Introduction
Dysregulation of tyrosine kinase receptor (TKR)-phos-
phatidylinositol 3-kinase (PI3K) signaling pathways is
frequent in human cancers. Among the most important
molecular events downstream of TKR activation is PI3K
activation, which catalyzes the phosphorylation of inosi-
tol lipids to phosphatidylinositol-3,4,5-trisphosphate.
Phosphatidylinositol-3,4,5-trisphosphate activates the
serine/threonine kinase AKT, which in turn regulates
several signaling pathways controlling cell survival,
apoptosis, proliferation, motility, and adhesion [1]. PI3K
is a heterodimeric enzyme composed of a p110a
catalytic subunit encoded by the PIK3CA gene and a
p85 regulatory subunit encoded by the PIK3R1 gene [2].
Recently, gain-of-function mutations in PIK3CA have
been found in several cancers, including breast cancer
[1,3,4]. PIK3CA is frequently mutated at ‘hotspots’ in
exons 9 and 20, corresponding to the helical (E542K
and E545K) and kinase (H1047R) domains, respectively.
P110a carrying a hotspot mutation shows oncogenic
activity: it can transform primary fibroblasts in culture,
induce anchorage-independent growth, and cause
tumors in animals [5,6].
After the TP53 suppressor gene, the PIK3CA onco-
gene is the most frequently mutated gene in human
breast cancers; mutations are observed in 20% to 40% of
cases [7,8]. Mutation is an early event in breast cancer
and is more likely to play a role in tumor initiation than
in invasive progression [9]. It is noteworthy that
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activating somatic mutations of other oncogenes (EGFR,
KRAS, HRAS, NRAF, BRAF, AKT1, and so on) involved
in molecular events downstream of TKR activation and
frequently observed in other cancers are rare in breast
cancer. Several studies of breast cancer suggest that
PIK3CA mutations are more frequent in estrogen recep-
tor-alpha- positive (ERa+) breast tumors (30% to 40%)
than in receptor-alpha-negative (ERa-) breast tumors
(10% to 20%) [3,7,10,11].
The prognostic value of PIK3CA mutation status in
breast cancer is controversial. Li and colleagues [12]
suggested that mutations in any part of the gene may be
related to poor clinical outcome. On the contrary, Mar-
uyama and colleagues [13], Pérez-Tenorio and collea-
gues [14], and Kalinsky and colleagues [11] suggested
that PIK3CA mutations were significantly and indepen-
dently associated with better recurrence-free survival. In
particular, Kalinsky and colleagues [11] studied a series
of 590 patients with breast cancer with a median follow-
up of 12.8 years and found 32.5% of PIK3CA mutations.
PIK3CA-mutated status was associated with markers of
good prognosis and with significant improvement in
overall (P = 0.03) and breast cancer-specific (P = 0.004)
survival [11]. A study focused specifically on recurrent
and metastatic breast cancer found a significant associa-
tion of PIK3CA mutations and longer relapse-free survi-
val [15]. Barbareschi and colleagues [16] reported that
only PIK3CA exon 9 mutations were independently
associated with early recurrence and death but that
exon 20 mutations were associated with favorable out-
come. Several teams have found no significant effect of
PIK3CA mutations on patient outcome [7,8,17,18]. It is,
however, noteworthy that Loi and colleagues [18] identi-
fied an expression signature derived from exon 20
PIK3CA-mutated tumors. This signature predicted bet-
ter outcome in ER+ breast cancer. In particular, the clin-
ical consequences of PIK3CA mutations might vary
according to the status of well-known molecular mar-
kers in breast cancer, namely ERa, progesterone recep-
tor (PR), and ERBB2. Here, we examined the prognostic
value of PIK3CA mutation status in a series of 452
patients with unilateral invasive primary breast cancer
and known long-term outcome, taking ERa, PR, and
ERBB2 status into account.
Materials and methods
Patients and samples
We analyzed samples of 452 primary unilateral invasive
primary breast tumors excised from women at the Insti-
tut Curie/Hôpital René Huguenin (Saint-Cloud, France)
from 1978 to 2008. All patients who entered our institu-
tion before 2007 were informed that their tumor sam-
ples might be used for scientific purposes and had the
opportunity to decline. Since 2007, patients entering our
institution have given their approval also by signed
informed consent. This study was approved by the local
ethics committee (Breast Group of René Huguenin Hos-
pital). The samples were examined histologically and
were considered suitable for this study if the proportion
of tumor cells exceeded 70% with sufficient cellularity as
was proven by evaluation of tumor samples stained by
hematoxylin and eosin. Immediately after surgery, the
tumor samples were placed in liquid nitrogen until RNA
extraction.
The patients (mean age of 61.6 years and range of 31
to 91) met the following criteria: primary unilateral non-
metastatic breast carcinoma, with full clinical, histologi-
cal and biological data; no radiotherapy or chemother-
apy before surgery; and full follow-up at Institut Curie/
Hôpital René Huguenin.
One hundred sixty patients (35.4%) had breast-conser-
ving surgery plus locoregional radiotherapy, and 292
patients (64.6%) had modified radical mastectomy. Clini-
cal examinations were performed every 3 or 6 months
during the first 5 years, according to the prognostic risk
of the patients, and then yearly. Mammograms were
done annually. Three hundred sixty-six patients received
adjuvant therapy, consisting of chemotherapy alone in
94 cases, hormone therapy alone in 177 cases, and both
treatments in 95 cases. None of the ERBB2+ patients
was treated with anti-ERBB2 therapy. The histological
type and number of positive axillary nodes were estab-
lished at the time of surgery. The malignancy of infil-
trating carcinomas was scored with the Scarff-Bloom-
Richardson histoprognostic system’.
ER and PR status was determined at the protein level
by using biochemical methods (dextran-coated charcoal
method or enzymatic immunoassay) until 1999 and later
by using immunohistochemistry. Cutoff for ER and PR
positivity was set at 15 fm/mg (dextran-coated charcoal
or enzyme immunoassay) and at 10% immunostained
cells (immunohistochemistry). A tumor was considered
ERBB2+ by immunohistochemistry if it scored 3 or
more with uniform intense membrane staining of
greater than 30% of invasive tumor cells. Tumors scor-
ing 2 or more were considered to be equivocal for
ERBB2 protein expression and were tested by fluores-
cence in situ hybridization for ERBB2 gene amplifica-
tion. In all cases, the ERa, PR, and ERBB2 status was
confirmed by real-time quantitative reverse transcrip-
tase-polymerase chain reaction (RT-PCR) with cutoff
levels based on previous studies comparing results of
the mentioned methods [19-22]. On the basis of hor-
mone receptor (HR) (ERa and PR) and ERBB2 status,
we subdivided the 452 patients into four subgroups: HR
+ (ER+ or PR+ or both)/ERBB2+ (n = 53), HR+ (ER+ or
PR+ or both)/ERBB2- (n = 287), HR- (ER- and PR-
)/ERBB2+ (n = 48), and HR- (ER- and PR-)/ERBB2- (n =
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64). Standard prognostic factors are reported in Table
S1 of Additional file 1. The median follow-up was 10.0
years (range of 13 months to 28.9 years). One hundred
seventy patients developed metastases.
RNA extraction
Total RNA was extracted from breast tumor samples by
using the acid-phenol guanidium method. RNA quantity
was assessed by using a NanoDrop Spectrophotometer
ND-1000 with its corresponding software (Thermo
Fisher Scientific Inc., Wilmington, DE, USA). RNA qual-
ity was determined by electrophoresis through agarose
gel and staining with ethidium bromide. The 18S and
28S RNA bands were visualized under ultraviolet light.
DNA contamination was quantified by using a couple of
primers located in an intron of gene coding for albumin
(ALB) (Gene ID: 213). Samples were further used only
when the cycle threshold (Ct) obtained by using these
ALB intron primers was greater than 40.
PIK3CA mutation screening
PIK3CA mutations were detected by screening cDNA
fragments obtained by RT-PCR amplification of exons 9
and 20 and their flanking exons. Details of the primers
and PCR conditions are available on request. The ampli-
fied products were sequenced with a BigDye Terminator
kit on an ABI Prism 3130 automatic DNA sequencer
(Applied Biosystems, Courtabæuf, France) with detec-
tion sensitivity of 5% mutated cells, and the sequences
were compared with the corresponding cDNA reference
sequence (NM_006218). All of the detected PIK3CA
mutations were confirmed in the second independent
run of sample testing.
Statistical analysis
Relationships between PIK3CA mutation status and clin-
ical, histological, and biological parameters were esti-
mated with the chi-squared test. Differences between
the mutated and non-mutated populations were judged
significant at confidence levels of greater than 95% (P <
0.05). Metastasis-free survival (MFS) was determined as
the interval between diagnosis and detection of the first
metastasis. Survival distributions were estimated with
the Kaplan-Meier method [23], and the significance of
differences between survival rates was ascertained with
the log-rank test [24]. The Cox proportional hazards
regression model [25] was used to assess prognostic
significance.
Results and Discussion
PIK3CA mutations were identified in 151 (33.4%) of
452 primary breast tumors, in keeping with the results
of the largest previous studies, showing mutation rates
of 25% to 40% [7,8,11,14,16,18,26-30]. Sixty-four
tumors bore PIK3CA mutations located in exon 9, 86
tumors bore mutations in exon 20, and one tumor
bore mutations in both exons 9 and 20 (Table 1). Exon
20 was thus the most frequently mutated PIK3CA
Table 1 PIK3CA mutation profiles
Exon Nucleotide Codon Number of mutations
9 c.1634A > C Glu545Ala 2
9 c.1636C > A Gln546Lys 2
9 c.1624 G > A Glu542Lys 20
9 c.1634A > G Glu545Gly 1
9 c.1633 G > A Glu545Lys 32
9 c.1633 G > C Glu545Gln 1
9 c.1490A > G Asn497Ser 1
9 c.1636C > A Gln546Lys 2
9 c.1637A > C Gln546Pro 1
9 c.1637A > G Gln546Arg 2
20 c.3203dupA Asn1068Lys 2
20 c.3140A > T His1047Leu 8
20 c.3140A > G His1047Arg 70
20 c.3132T > A Asn1044Lys 1
20 c.3145 G > C Gly1049Arg 2
20 c.3155C > A Thr1052Lys 1
20 c.[3085 > C(+)3140A > T] p.[Asp1029His(+)His1047Leu] 1
20 c.[3140A > T(+)3197C > T] p.[His1047Leu(+)Ala1066Val] 1
9+20 c.[1624 G < A(+)3127A > G] p.[Glu542Lys(+)Met1043Val] 1
Total = 151
PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide gene.
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exon, in keeping with most other studies
[7,8,11,14,26,28-30]. Among the 151 tumors with
PIK3CA mutations, three bore double mutations: two
in exon 20 (D1029H and H1047R, H1047R and
A1066V) and one in exons 9 and 20 (E542K and
M1043V). Rare double PIK3CA mutations have been
reported elsewhere [7,8,30]. We also observed two
c.3203dupA frameshift mutations that would change
the last C-terminal amino acid (N1068K) of the
PIK3CA protein and add another three amino acids.
N1068K represents 50% of all PIK3CA mutations in
hepatocellular carcinoma [28] but its possible role in
tumor initiation or progression is unknown.
Table 2 shows links between PIK3CA mutation status
and standard clinical, pathological, and biological char-
acteristics of breast cancer. PIK3CA mutations were sig-
nificantly associated (chi-squared test) with low
histopathological grade, small macroscopic tumor size,
and ERa+, PR+, and ERBB2- tumors. For example,
PIK3CA mutations were observed in 52.7% (29 out of
55) of histopathological grade I tumors, 36.8% (84 out
of 228) of grade II tumors, and 23.3% (37 out of 159) of
grade III tumors. These relationships have also been
found in most previous studies [3,7,10,11]. For example,
Kalinsky and colleagues [11], like us, found that PIK3CA
mutations were associated with low histopathological
grade and ERa+, PR+, and ERBB2- tumors. However, it
is noteworthy that, in several studies, no significant
association between PIK3CA mutations and important
clinical or pathological features was found [30]. A high
frequency of PIK3CA mutations has also been found in
lobular carcinoma [16,31]. In agreement with other
authors [27,30], we observed a similar frequency of
PIK3CA mutations in lobular carcinomas (34.5%, 10 out
of 29) and ductal carcinomas (33.2%, 129 out of 388) of
the breast (Table 2).
Table 2 Relationship between PIK3CA mutation status and standard clinical, pathological, and biological features of
breast cancer
Number of patients (percentage)
Total population number (percentage) PIK3CA wild-type PIK3CA-mutated P valuea
Total 452 (100.0) 301 (66.6) 151 (33.4)
Age, years
≤ 50 96 (21.2) 66 (21.9) 30 (19.9) NS
> 50 356 (78.8) 235 (78.1) 121 (81.1)
SBR histological gradeb, c
I 55 (12.4) 26 (8.9) 29 (19.3) 0.00021
II 228 (51.6) 144 (49.3) 84 (56.0)
III 159 (36.0) 122 (41.8) 37 (24.7)
Lymph node statusd
0 115 (25.5) 78 (26.0) 37 (24.5)
1-3 237 (52.5) 157 (52.3) 80 (53.0)
> 3 99 (22.0) 65 (21.7) 34 (22.5) NS
Macroscopic tumor sizee
≤ 25 mm 217 (48.8) 135 (45.2) 82 (56.2) 0.029
> 25 mm 228 (51.2) 164 (54.8) 64 (43.8)
ERa status
Negative 117 (25.9) 97 (32.2) 20 (13.2) 0.000014
Positive 335 (74.1) 204 (67.8) 131 (86.8)
PR status
Negative 194 (42.9) 150 (49.8) 44 (29.1) 0.000028
Positive 258 (57.1) 151 (50.2) 107 (70.9)
ERBB2 status
Negative 351 (77.7) 225 (74.8) 126 (83.4) 0.036
Positive 101 (22.3) 76 (25.2) 25 (16.6)
Histology
Ductal 388 (85.8) 259 (86.0) 129 (85.5) NS
Lobular 29 (6.4) 19 (6.3) 10 (6.6)
Others 35 (7.8) 23 (7.7) 12 (7.9)
aChi-squared test. bScarff-Bloom-Richardson (SBR) classification. cInformation available for 442 patients. dInformation available for 451 patients. eInformation
available for 445 patients. ERa, estrogen receptor-alpha; NS, not significant; PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha polypeptide gene; PR,
progesterone receptor.
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Functional genomic studies have recently shown that
breast cancer is a highly heterogeneous disease. Several
tumor subtypes, such as basal-like, ERBB2+, and HR+
(luminal A and luminal B), can be distinguished on the
basis of their gene expression profiles, pointing to the
involvement of different oncogenetic pathways. In keep-
ing with this possibility, we observed a marked differ-
ence in the PIK3CA mutation frequency across four
major tumor subgroups: HR+/ERBB2+ (28.3%, 15 out of
53), HR+/ERBB2- (41.1%, 118 out of 287), HR-/ERBB2+
(20.8%, 10 out of 48), and HR-/ERBB2- (12.5%, 8 out of
64) (P = 0.00009). Being found in 41.1% of cases,
PIK3CA mutations might thus be characteristic of the
luminal subtype (HR+/ERBB2-). We also observed a low
frequency (12.5%) of PIK3CA mutations in triple-nega-
tive tumors (ER-/PR-/ERBB2-), a subgroup reported to
overlap with the basal-like subtype of breast cancer.
Stemke-Hale and colleagues [8] also observed a marked
difference in PIK3CA mutation frequency across breast
tumor subtypes, and PIK3CA mutations were more
common in HR+ tumors (39%) and ERBB2+ tumors
(25%) than in basal-like tumors (13%).
In the overall population of 452 patients, PIK3CA
mutation was associated with more favorable MFS (P =
0.0056) (Table 3 and Figure 1a). The outcome of the
151 patients with PIK3CA mutations was thus signifi-
cantly better than that of the 301 wild-type patients, as
was demonstrated by 5-year and 15-year survival rates
in these two groups (5-year MFS of 81.0% versus 69.6%
and 15-year MFS of 65.8% versus 53.4%). Differences in
treatment are unlikely to account for this difference, as
PIK3CA mutations were as frequent in patients who
received postoperative adjuvant chemotherapy or hor-
mone therapy or both (126 out of 366, 34.4%) as in
those who received neither treatment (25 out of 86,
29.1%).
These data confirm the results of smaller series of
breast tumors, in which PIK3CA mutations were signifi-
cantly associated with more favorable MFS [13,14].
However, unlike Barbareschi and colleagues [16], who
found that mutations in the helical (exon 9) and kinase
(exon 20) domains of the PIK3CA gene had different
prognostic values, we found that MFS was similar in
patients with mutations in one exon or the other when
we compared these two subgroups together and with
the wild-type subgroup (Figure 1b).
More interestingly, PIK3CA mutation was associated
with markedly better MFS in the patients with PR+
tumors (P = 0.0064) than in those with PR- tumors (P =
0.71) (Table 3 and Figure 2a) and also in patients with
ERBB2+ tumors (P = 0.014) than in those with ERBB2-
tumors (P = 0.12) (Table 3 and Figure 2b). In contrast,
PIK3CA mutation was associated only with a trend
toward better MFS in patients with ERa+ (P = 0.082)
and ERa- (P = 0.098) tumors (Table 3). Accordingly, Loi
and colleagues [18] did not find statistically significant
difference in survival between PIK3CA wild-type and
PIK3CA-mutated tumors in the ER+ population. How-
ever, it is noteworthy that these authors described a
PIK3CA mutation-associated gene expression signature
predicting favorable survival in ER+ breast cancer [18].
Using a Cox proportional hazards model, we also
assessed the MFS predictive value of the parameters
that were significant in univariate analysis (that is,
Scarff-Bloom-Richardson histological grade, lymph node
status, macroscopic tumor size, and ERa, PR, and
ERBB2 status (Table S1 of Additional file 1) and
PIK3CA mutation status). The prognostic significance of
PIK3CA mutation status persisted in the ERBB2+ tumor
subgroup (P = 0.023) (Table 4) but not in the total
tumor population or in the PR+ tumor subgroup. Since
the patients were not treated with ERBB2-targeted
Table 3 PIK3CA mutation status according to hormone











Wild-type 301 69.6% 1 0.0056
Mutated 151 81.0% 0.62 (0.44-
0.87)
ERa+ 335
Wild-type 204 75.6% 1 NS
Mutated 131 81.9% 0.71 (0.49-
1.04)
ERa- 117
Wild-type 97 56.9% 1 NS
Mutated 20 75.0% 0.46 (0.18-
1.15)
PR+ 258
Wild-type 151 77.8% 1 0.0064
Mutated 107 86.6% 0.52 (0.33-
0.83)
PR- 194
Wild-type 150 61.3% 1 NS
Mutated 44 67.6% 0.91 (0.55-
1.50)
ERBB2+ 101
Wild-type 76 59.9% 1 0.014
Mutated 25 88.0% 0.31 (0.12-
0.79)
ERBB2- 351
Wild-type 225 72.9% 1 NS
Mutated 126 79.7% 0.75 (0.51-
1.08)
aUnivariate Cox analysis. CI, confidence interval; ERa, estrogen receptor-alpha;
HR, hazard ratio; MFS, metastasis-free survival; NS, not significant; PR,
progesterone receptor.
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Figure 1 Whole population survival curves. (a) Metastasis-free survival curves of patients with PIK3CA wild-type and -mutated tumors. (b)
Metastasis-free survival curves of patients with exon 9 PIK3CA-mutated tumors, exon 20 PIK3CA-mutated tumors, and PIK3CA wild-type tumors.























































Figure 2 Subgroup analysis survival curves. (a) Metastasis-free survival curves of progesterone receptor-positive (PR+) patients with PIK3CA
wild-type and -mutated tumors. (b) Metastasis-free survival curves of ERBB2+ patients with PIK3CA wild-type and -mutated tumors. PIK3CA,
phosphatidylinositol 3-kinase, catalytic, alpha polypeptide gene.
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treatment, these results address the outcome of ERBB2+
tumors affected by surgery and chemotherapy but not
targeted therapy like trastuzumab or lapatinib. The inde-
pendent prognostic value of PIK3CA mutation status in
patients with ERBB2+ breast cancer should now be
tested in a larger series of patients included in rando-
mized prospective ERBB2-based clinical trials.
PIK3CA mutation is also an emerging tumor marker
that, in the future, might be used in the process of
choosing a treatment. Indeed, ERBB2 inhibitors
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aMultivariate Cox analysis. CI, confidence interval; ER, estrogen receptor; HR, hazard ratio; NS, not significant; PIK3CA, phosphatidylinositol 3-kinase, catalytic, alpha
polypeptide gene; pN, number of positive axillary lymph nodes assessed by a pathologist at the time of surgery; PR, progesterone receptor; pT, size of the
primery tumor assessed by a patologist at the time of surgery}; SBR, Scarff-Bloom-Richardson classification.
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(trastuzumab and lapatinib) are clinically active in
women with ERBB2+ breast cancer, but recent studies
suggest that PIK3CA-mutated tumors could be resistant
to these drugs [32,33]. There is also evidence showing
that tumors with PI3K/AKT pathway activation includ-
ing PTEN loss or PIK3CA mutation or both are less
sensitive to trastuzumab treatment [17]. Interestingly,
this resistance appears to be reversed by mammalian
target of rapamycin (mTOR) or PI3K inhibitors [33]. A
final validation of PIK3CA mutation as an independent
predictor of the response to trastuzumab treatment in
ERBB2+ breast cancer needs a prospective randomized
study. Our results also support the emerging role of
PIK3CA mutation status in the management of future
gene-based therapies (ERBB2, mTOR, or PI3K inhibitors
used alone or in combination) for breast cancer, particu-
larly in patients with tumors with activated PI3K/AKT
pathway [34,35]. ERBB2 amplification and PIK3CA
mutation were recently validated as biomarkers of sensi-
tivity to single-agent PI3K inhibitor (GDC-0941) therapy
in breast cancer models [35].
Conclusions
This study of 452 breast tumors confirms the high pre-
valence (33.4%) of PIK3CA mutations. The frequency of
PIK3CA mutations differed markedly according to ERa,
PR, and ERBB2 status, from 12.5% in triple-negative
tumors to 41.1% in the HR+/ERBB2- subgroup. Sub-
group analysis of patient survival identified PIK3CA
mutation status as an independent prognostic value in
patients with ERBB2+ breast cancer. These findings
should be confirmed in larger series of patients included
in a randomized prospective ERBB2-based clinical trial.
Then PIK3CA mutation status could serve as a new
independent prognostic tool when selecting targeted
therapies for patients with ERBB2+ breast cancer.
Additional material
Additional file 1: Table S1. Characteristics of the 452 primary breast
tumors, and relation to metastasis-free survival. A table showing
metastasis free survival of the patients in relation to pathological data.
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